References [1] Dabbs T. ( 2014 ), The True Cost of Maintenance . Pump & Systems [2
facilities management in business performance 2011 Róka-Madarász L. Performance measurement for maintenance management of real
highways, Code of practice for highway maintenance management, London, The Stationary Office (TSO), 2005. [5] Economic Development Research Group , Failure to act, The impact of current infrastructure
Bako A. Decision supporting model for highway maintenance, Acta Politechnica Hungarica , Vol. 1, 2004, pp. 96–108. Bako A. Decision supporting model for highway maintenance
Spencer, H. G. (1991): The maintenance of single-locus polymorphism. II. The evolution of fitnesses and allele frequencies. Amer. Nat. 138 :1354-1371. The maintenance of single-locus polymorphism. II. The evolution of fitnesses
. (2013), Sabir (2012), and Yuan et al. (2010) suggesting the application of combined treatments with 1-MCP and low temperature cold storage for quality maintenance of fresh broccoli. Conclusions The effects of 1-MCP, ethylene and 1-MCP followed by
. (2013), Sabir (2012), and Yuan et al. (2010) suggesting the application of combined treatments with 1-MCP and low temperature cold storage for quality maintenance of fresh broccoli. Conclusions The effects of 1-MCP, ethylene and 1-MCP followed by
Hematol. 2020; 13: 351–362. 2 Diamond B, Maclachlan K, Chung DJ, et al. Maintenance therapy and need for cessation studies in multiple myeloma: focus on
hemodialysis patients and the control Hepcidin (ng/mL) AOPP (ng/mL) IL-6 (pg/mL) Control 84.7 (49.6–179.3) 78.8 (51.3–139.4) 33.5 (22.4–47.6) MHD group 249.2 (169.0–475.2) * 336.6 (249.6–389.6) * 45.9 (32.8–85.4) * Note : maintenance hemodialysis (MHD
Összefoglaló. Az autológ őssejt-transzplantáció után visszaeső diffúz nagy B-sejtes limfómás betegek kezelése nagy kihívást jelent. Az újabban alkalmazott kismolekulák, illetve a CAR-T-sejtes terápia ígéretes kezelési lehetőségek, de ezekkel még nincs megfelelő tapasztalat, illetve csak bizonyos betegcsoportban alkalmazhatók. A munkában egy autológ hemopoetikus őssejt-transzplantáció után visszaeső diffúz nagy B-sejtes limfómás beteg sikeres kezelését mutatják be a szerzők rituximab-bendamustin-venetoclax kombinációs indukciós terápiával, amit 1 éves fenntartó venetoclaxkezelés követett. A beteg a kezelést végig jól tolerálta, tartós remisszió alakult ki. Az eset jól példázza, hogy az új kismolekulák alkalmazása nemcsak az indukcióban, hanem fenntartó kezelésként is szóba jöhet egyes betegekben.
Summary. Treatment of patients with relapse of diffuse large B-cell lymphoma after autologous stem cell transplantation is a major challenge. Recently used small molecules and CAR-T-cell therapy are promising treatment options, but are not always available, and can only be used in certain groups of patients. In this paper the authors demonstrate the successful treatment of a relapsed diffuse large B-cell lymphoma patient after autologous hematopoietic stem cell transplantation with rituximab-bendamustine-venetoclax induction therapy for 6 cycles, followed by 12 months venetoclax maintenance therapy. The patient tolerated the induction and maintenance well, a sustained complete remission was achieved. The case highlights the possible implication of the novel small molecules not only in induction but maintenance treatment as well.
